Regencell Bioscience Holdings Limited (RGC)

RGC Financials Overview

Financials in millions USD. Fiscal year is July - June.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Operating Income Operating Income Growth	-11.72	-11.72	-3.77	-4.74	-6.27	-7.62
Net Income Net Income Growth	-11.7	-11.7	-3.58	-4.3	-5.87	-7.45
Earnings Per Share EPS Growth	-0.02	-0.02	-0.01	-0.01	-0.01	-0.02
EPS Growth	-	-	-	-	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Cash & Investments Cash & Investments Growth	14.19	14.19	4.9	7.96	11.56	16.42
Total Debt Total Debt Growth	0.3	0.3	0.54	0.09	0.46	0.77
Net Cash (Debt) Net Cash Growth	13.9	13.9	4.35	7.88	11.1	15.65
Net Cash Growth	605.09%	219.27%	-44.73%	-29.06%	-29.05%	-
Net Cash Per Share Net Cash Per Share Growth	0.03	0.03	0.01	0.02	0.02	0.03

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Operating Cash Flow Operating Cash Flow Growth	-7.7	-7.7	-3.11	-4	-4.96	-5.27
Capital Expenditures CapEx Growth	-	-	-0.15	-0.01	-0.03	-0.78
Free Cash Flow Free Cash Flow Growth	-7.7	-7.7	-3.27	-4.01	-4.99	-6.05
Free Cash Flow Growth	-	-	-	-	-	-

Valuation

Selected indicators aren't available for this stock.

Data Source: S&P Global Market Intelligence Last updated: Oct 7, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 19, 2026

Data Sources Report a data error